Sign in Subscribe
Banks (Finance)

European Investment Bank and BioNTech Conclude EUR100M Debt Financing Agreement for COVID-19 Vaccine Programme

Strategic Insights

— 2 min read

The European Investment Bank (EIB) and BioNTech SE have concluded a EUR100 million debt financing agreement to support the development of BioNTech's COVID-19 vaccine program, BNT162. This funding will enable BioNTech to scale-up its manufacturing capacity in Europe to supply the vaccine globally in response to the pandemic. The agreement also supports the ongoing clinical development of BNT162, which has already entered clinical testing in Germany and the United States.

Key Takeaways:

  • The EIB debt financing agreement of EUR100 million will support the development of BioNTech's COVID-19 vaccine program, BNT162, and enable the company to scale-up its manufacturing capacity in Europe.
  • The agreement will be disbursed in two tranches of EUR50 million each, following completion of pre-defined milestones.
  • BioNTech's development programme for BNT162 is one of the broadest development programmes globally, with four vaccine candidates being tested in parallel.
  • mRNA vaccines are a potent new developmental class of vaccines with potential for high versatility and favourable safety properties.
  • BioNTech has brought the first vaccine candidates from concept into clinical testing in less than three months.
  • The EIB debt investment will be backed by the European Fund for Strategic Investments and will benefit from InnovFin Risk Sharing for Corporate Research backed by Horizon 2020.
  • The partnership between the EIB and BioNTech is part of the EU's efforts to counter the spread of the coronavirus and mobilise significant funding for research projects.

Statistics:

  • EUR100 million debt financing agreement between the EIB and BioNTech to support the development of BNT162.
  • Two tranches of EUR50 million each to be disbursed following completion of pre-defined milestones.
  • Four vaccine candidates being tested in parallel in BioNTech's clinical development programme for BNT162.
  • mRNA vaccines have the potential to be highly versatile and have favourable safety properties.
  • BioNTech has developed vaccine candidates from concept to clinical testing in less than three months.

Sources:

  • "European Investment Bank and BioNTech SE have concluded a EUR100 million debt financing agreement to support the development of BioNTech's COVID-19 vaccine program, BNT162." - GlobeNewswire
  • "The agreement also supports the ongoing clinical development of BNT162, which has already entered clinical testing in Germany and the United States." - GlobeNewswire
  • "BioNTech's development programme for BNT162 is one of the broadest development programmes globally, with four vaccine candidates being tested in parallel." - GlobeNewswire
  • "mRNA vaccines are a potent new developmental class of vaccines with potential for high versatility and favourable safety properties." - GlobeNewswire
  • "BioNTech has brought the first vaccine candidates from concept into clinical testing in less than three months." - GlobeNewswire
  • "The EIB debt investment will be backed by the European Fund for Strategic Investments and will benefit from InnovFin Risk Sharing for Corporate Research backed by Horizon 2020." - GlobeNewswire
  • "The partnership between the EIB and BioNTech is part of the EU's efforts to counter the spread of the coronavirus and mobilise significant funding for research projects." - GlobeNewswire

Read more